Hello, fellow rebel capitalists, hope you're well. I know this may come as a surprise to you,

but Pfizer just announced they had record revenues for 2022.

A shocker, I know, I know.

But let's get into this article from CMBC go over kind of how much money they made.

And I think this should prompt people to start asking some questions.

Or maybe they already are asking questions and I think that's good.

I think that's healthy. I think that's what we need. A debate going back and forth

about what on earth just happened. I'm talking about 20-20 and 2021. So let's get into this article from

C and B. C. Title the Servesa sickness drives Pfizer 2022 revenue to record 100 billion. 100 billion.

I granted that's not net but I would imagine their margins are astronomical

because it's almost like software.

Like it's it the margins aren't that high obviously but my point is once you

create one piece of software you can sell it infinitely for pretty much no additional price other than just

marketing and whatnot where once you create a drug I would assume that creating more of that drug is a very low cost relative to what you're

selling it for. The cost of goods sold is what I'm talking about is extremely low

it's just most of the cost with that drug is kind of front-loaded might be the

right way to say it so let's see if we can get into what their margins were and what that meant for the bottom line, but still 100 billion no matter how you break it down. It's going to be, well, I shouldn't say that it's always going to be net profit,

but it most likely will mean a significant amount of profit.

So key talking points, Pfizer sold 37.8 billion of its Cervaisa Sickness Medicine last year, a small

increase of 3% compared to 2021. Sales of Hax Lovid, however, surged to 18.9 billion in 2022.

Now you say, well, what is Pax Loved?

I've heard of that, but I really haven't done too much research on it.

...